問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
廖子堯
下載
2025-11-01 - 2033-12-31
Condition/Disease
Locally advanced unresectable or metastatic HER2-overexpressing non-squamous non-small cell lung cancer
Test Drug
Trastuzumab Deruxtecan(AZD4552 DS-8201A)
Participate Sites9Sites
Recruiting9Sites
2025-11-19 - 2030-06-30
Platinum-based therapy-resistant epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
Navicixizumab
Participate Sites10Sites
Recruiting10Sites
2025-03-01 - 2029-03-01
Participate Sites14Sites
Recruiting14Sites
2024-01-01 - 2030-06-30
2021-10-01 - 2027-06-30
Participate Sites16Sites
Recruiting16Sites
2024-04-01 - 2036-01-31
Participate Sites1Sites
Recruiting1Sites
2025-08-31 - 2028-08-31
Participate Sites3Sites
Recruiting3Sites
2024-01-22 - 2027-05-27
Participate Sites12Sites
Not yet recruiting1Sites
Recruiting11Sites
2022-04-15 - 2027-04-30
Participate Sites4Sites
Recruiting4Sites
2026-02-01 - 2034-11-14
Participate Sites8Sites
Recruiting7Sites
全部
